FDA Approves Subcutaneous Multiple Myeloma Treatment with On-Body Injector

The U.S. FDA has approved isatuximab-irfc for subcutaneous administration in multiple myeloma patients. This marks a significant advancement as it is the first anticancer therapy to be delivered via an on-body injector, potentially offering greater convenience and improved quality of life for patients. This new method could reduce the need for frequent intravenous infusions.